# Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

> **NCT02597153** · PHASE2 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Relapsed Cutaneous T Cell Lymphom

## Interventions

- **DRUG:** Mitoxantrone HCL Liposome Injection

## Key facts

- **NCT ID:** NCT02597153
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-10
- **Final completion:** 2020-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Just one subject enrolled in this trial during one and a half years.
- **Last updated:** 2017-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597153, "Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02597153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*